Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.19
-0.11 (-1.75%)
At close: Mar 27, 2026, 4:00 PM EDT
6.20
+0.01 (0.16%)
After-hours: Mar 27, 2026, 4:04 PM EDT
Profound Medical Revenue
In the year 2025, Profound Medical had annual revenue of $16.10M with 50.73% growth. Profound Medical had revenue of $5.98M in the quarter ending December 31, 2025, with 61.32% growth.
Revenue (ttm)
$16.10M
Revenue Growth
+57.68%
P/S Ratio
13.93
Revenue / Employee
$99,370
Employees
162
Market Cap
224.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | 5.42M | 50.73% |
| Dec 31, 2024 | 10.68M | 3.48M | 48.35% |
| Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
| Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
| Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
| Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
| Dec 31, 2019 | 4.17M | 2.26M | 117.58% |
| Dec 31, 2018 | 1.92M | -1.98M | -50.81% |
| Dec 31, 2017 | 3.90M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inogen | 348.67M |
| InfuSystem Holdings | 143.44M |
| RxSight | 134.48M |
| Sight Sciences | 77.36M |
| Electromed | 68.86M |
| CVRx, Inc. | 56.65M |
| 908 Devices | 56.20M |
| TriSalus Life Sciences | 45.15M |
PROF News
- 2 days ago - Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone - GlobeNewsWire
- 9 days ago - Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
- 16 days ago - Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript - Seeking Alpha
- 16 days ago - Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes - GuruFocus
- 16 days ago - CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence - GlobeNewsWire
- 20 days ago - Profound Medical (PROF) Awaits Key Clinical Data Presentation - GuruFocus
- 23 days ago - Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - GuruFocus